Clinical trials: Oligometastases
Prostate Cancer, Oligometastases
Stereotactic Body Radiation for Prostate Oligometastases
Men with oligometastatic prostate cancer lesions will be randomized (1:2) to observation versus SBRT. The study will NOT be blinded. Within three weeks of the initial treatment planning, SBRT (1-5 fractions) will be administered.
- Trial name
- ORIOLE (NCT02680587)
- Testing
- SBRT
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oligometastases
Stereotactic Body Radiation With Nelfinavir for Oligometastases
Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered.
- Trial name
- NCT01728779
- Testing
- Nelfinavir, Stereotactic Body Radiation (SBRT)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oligometastases of the Spine
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
In light of the increasing experience with magnetic resonance image-guided radiotherapy (MRgRT) and adaptive planning and advances in magnetic resonance (MR)-only planning, the investigators propose here to evaluate the…
- Trial name
- NCT03878485
- Testing
- MRIdian Linac System from ViewRay, Stereotactic MRI-guided Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine